OBJECTIVE: To determine the clinical manifestations and disease damage associated with discoid rash in a large multiethnic systemic lupus erythematosus (SLE) cohort. METHODS: SLE patients (per American College of Rheumatology [ACR] criteria) ages ≥16 years with a disease duration of ≤10 years at enrollment and defined ethnicity (African American, Hispanic, or white) from a longitudinal cohort were studied. Socioeconomic-demographic features, clinical manifestations, and disease damage (per the Systemic Lupus International Collaborating Clinics/ACR Damage Index) were determined. The association of discoid lupus erythematosus (DLE) with clinical manifestations and disease damage was examined using multivariable logistic regression. RESULTS: A total of 2,228 SLE patients were studied. The mean ± SD age at diagnosis was 34.3 ± 12.8 years and the mean ± SD disease duration was 7.9 ± 6.0 years; 91.8% were women. DLE was observed in 393 patients with SLE (17.6%). In the multivariable analysis, patients with DLE were more likely to be smokers and of African American ethnicity and to have malar rash, photosensitivity, oral ulcers, leukopenia, and vasculitis. DLE patients were less likely to be of Hispanic (from Texas) ethnicity and to have arthritis, end-stage renal disease, and antinuclear, anti-double-stranded DNA, and antiphospholipid antibodies. Patients with DLE had more damage accrual, particularly chronic seizures, scarring alopecia, scarring of the skin, and skin ulcers. CONCLUSION: In this cohort of SLE patients, DLE was associated with several clinical features, including serious manifestations such as vasculitis and chronic seizures.
OBJECTIVE: To determine the clinical manifestations and disease damage associated with discoid rash in a large multiethnic systemic lupus erythematosus (SLE) cohort. METHODS:SLEpatients (per American College of Rheumatology [ACR] criteria) ages ≥16 years with a disease duration of ≤10 years at enrollment and defined ethnicity (African American, Hispanic, or white) from a longitudinal cohort were studied. Socioeconomic-demographic features, clinical manifestations, and disease damage (per the Systemic Lupus International Collaborating Clinics/ACR Damage Index) were determined. The association of discoid lupus erythematosus (DLE) with clinical manifestations and disease damage was examined using multivariable logistic regression. RESULTS: A total of 2,228 SLEpatients were studied. The mean ± SD age at diagnosis was 34.3 ± 12.8 years and the mean ± SD disease duration was 7.9 ± 6.0 years; 91.8% were women. DLE was observed in 393 patients with SLE (17.6%). In the multivariable analysis, patients with DLE were more likely to be smokers and of African American ethnicity and to have malar rash, photosensitivity, oral ulcers, leukopenia, and vasculitis. DLE patients were less likely to be of Hispanic (from Texas) ethnicity and to have arthritis, end-stage renal disease, and antinuclear, anti-double-stranded DNA, and antiphospholipid antibodies. Patients with DLE had more damage accrual, particularly chronic seizures, scarring alopecia, scarring of the skin, and skin ulcers. CONCLUSION: In this cohort of SLEpatients, DLE was associated with several clinical features, including serious manifestations such as vasculitis and chronic seizures.
Authors: Shyamal Wahie; Ann K Daly; Heather J Cordell; Mark J Goodfield; Stephen K Jones; Christopher R Lovell; Andrew J Carmichael; Mary M Carr; Angela Drummond; Sivakumar Natarajan; Catherine H Smith; Nick J Reynolds; Simon J Meggitt Journal: J Invest Dermatol Date: 2011-07-07 Impact factor: 8.551
Authors: D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; P Fortin; E Ginzler; C Gordon; J G Hanly; D A Isenberg; M Petri; O Nived; M Snaith; G Sturfelt Journal: J Rheumatol Date: 2000-02 Impact factor: 4.666
Authors: Joseph F Merola; Stephen D Prystowsky; Christina Iversen; Jose A Gomez-Puerta; Tabatha Norton; Peter Tsao; Elena Massarotti; Peter Schur; Bonnie Bermas; Karen H Costenbader Journal: J Am Acad Dermatol Date: 2013-03-28 Impact factor: 11.527
Authors: Fatima Alduraibi; Huma Fatima; Jennie A Hamilton; W Winn Chatham; Hui-Chen Hsu; John D Mountz Journal: Arthritis Res Ther Date: 2022-04-18 Impact factor: 5.606